https://www.pharmaradar360.com/article/why-the-direct-model-is-the-future-of-pharma-1-fcd00c1bcd20f657Pharma Surgeen2026-07-09T16:13:12.000ZWhy the Direct Model is the Future of Pharma(1)https://www.pharmaradar360.com/article/stocks-look-shaky-but-this-sector-is-booming-biotech-1e36968c8e4376a9Pharma Surgeen2026-07-09T16:11:04.000ZStocks Look Shaky, But This Sector is Booming (Biotech)https://www.pharmaradar360.com/article/sino-and-astrazeneca-sign-licence-agreement-for-tqc3721-ede08d1ecad9675fPharma Surgeen2026-07-09T15:51:00.000ZSino and AstraZeneca sign licence agreement for TQC3721https://www.pharmaradar360.com/article/jim-cramer-says-biotech-is-the-hottest-group-in-the-market-right-now-b97b6d1fc82fb58dPharma Surgeen2026-07-09T15:46:21.000ZJim Cramer Says Biotech is The Hottest Group in The Market Right Nowhttps://www.pharmaradar360.com/article/why-the-pharmacy-experience-matters-for-glp-1-outcomes-d9876092ad73a96bPharma Surgeen2026-07-09T15:38:12.000ZWhy the Pharmacy Experience Matters for GLP-1 Outcomeshttps://www.pharmaradar360.com/article/jim-cramer-says-biotech-is-the-hottest-group-in-the-market-right-now-8e94fb0662c8a0a2Pharma Surgeen2026-07-09T15:35:25.000ZJim Cramer Says Biotech is The Hottest Group in The Market Right Nowhttps://www.pharmaradar360.com/article/as-ramaswamy-vacations-in-europe-biotech-he-founded-collects-950m-covid-vaccine-883ac449d0ed0a52Pharma Surgeen2026-07-09T15:10:00.000ZAs Ramaswamy vacations in Europe, biotech he founded collects $950M COVID vaccine paymenthttps://www.pharmaradar360.com/article/arialys-therapeutics-announces-u-s-fda-fast-track-designation-for-art5803-the-fi-44d0d3cc6ba0be70Pharma Surgeen2026-07-09T15:08:09.000ZArialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitishttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-63ff575955c0b169Pharma Surgeen2026-07-09T15:07:56.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, October 2026 to October 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-dd9b886471b7e27ePharma Surgeen2026-07-09T15:07:39.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, September 2026 to September 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-e29136a0758c031fPharma Surgeen2026-07-09T15:07:28.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2026 to August 2027https://www.pharmaradar360.com/article/depression-drug-approved-by-fda-had-11-failed-trials-and-an-advisory-committee-v-fb6743728e10c812Pharma Surgeen2026-07-09T15:07:28.000ZDepression Drug Approved by FDA Had 11 Failed Trials and an Advisory Committee Vote Against Approvalhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-e4a658a591d9a33ePharma Surgeen2026-07-09T15:07:15.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, July 2026 to July 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-a0324311fd4d4714Pharma Surgeen2026-07-09T15:07:01.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2026 to June 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-2e45bd7b86003737Pharma Surgeen2026-07-09T15:06:38.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, May 2026 to May 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-b7f6f80136a72c29Pharma Surgeen2026-07-09T15:05:52.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, April 2026 to April 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-a9688d88c3a30590Pharma Surgeen2026-07-09T15:05:20.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, March 2026 to March 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-df1ca0002f7ddc6bPharma Surgeen2026-07-09T15:05:05.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, February 2026 to February 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-6665f6d4d545e2adPharma Surgeen2026-07-09T15:04:46.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, January 2026 to January 2027https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-b514e806327cec75Pharma Surgeen2026-07-09T15:04:29.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, December 2025 to December 2026https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-9bc61a228a7791a8Pharma Surgeen2026-07-09T15:04:06.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, November 2025 to November 2026https://www.pharmaradar360.com/article/nhs-resolution-annual-report-and-accounts-2025-to-2026-9fb1d190d44240abPharma Surgeen2026-07-09T14:57:03.000ZNHS Resolution annual report and accounts: 2025 to 2026https://www.pharmaradar360.com/article/structuring-tech-transfer-for-optimized-collaboration-f681cd65b348ed55Pharma Surgeen2026-07-09T14:41:34.000ZStructuring Tech Transfer for Optimized Collaborationhttps://www.pharmaradar360.com/article/uk-health-security-agency-ukhsa-research-involving-animals-d1a35b4ab386d009Pharma Surgeen2026-07-09T14:41:22.000ZUK Health Security Agency (UKHSA) research involving animalshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-95407ca4abeca4e9Pharma Surgeen2026-07-09T14:37:28.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/marburg-and-ebola-contact-tracing-matrix-86b4f06f6555d1e2Pharma Surgeen2026-07-09T14:30:00.000ZMarburg and Ebola contact tracing matrixhttps://www.pharmaradar360.com/article/crimean-congo-haemorrhagic-fever-cchf-contact-tracing-matrix-4a84aeef62e16262Pharma Surgeen2026-07-09T14:30:00.000ZCrimean-Congo haemorrhagic fever (CCHF) contact tracing matrixhttps://www.pharmaradar360.com/article/paxlovid-safe-for-children-aged-6-and-older-new-study-finds-c14e725c039055efPharma Surgeen2026-07-09T14:30:00.000ZPaxlovid Safe for Children Aged 6 And Older, New Study Findshttps://www.pharmaradar360.com/article/regulators-push-amgen-to-withdraw-drug-due-to-data-manipulation-ab29bf085d70abf5Pharma Surgeen2026-07-09T14:15:00.000ZRegulators push Amgen to withdraw drug due to data manipulationhttps://www.pharmaradar360.com/article/prime-wins-beam-arbitration-clearing-path-to-clinic-9394e079194e3638Pharma Surgeen2026-07-09T14:06:57.000ZPrime wins Beam arbitration, clearing path to clinichttps://www.pharmaradar360.com/article/lilly-was-already-pharma-s-biggest-company-now-it-s-doing-deals-to-match-7051dfd83f0d8e5aPharma Surgeen2026-07-09T14:00:00.000ZLilly was already pharma's biggest company. Now it's doing deals to matchhttps://www.pharmaradar360.com/article/serum-institute-of-india-ties-up-with-dndi-for-phase-iii-trial-of-dengue-therapy-82db2368ff3edeccPharma Surgeen2026-07-09T13:58:26.000ZSerum Institute of India ties up with DNDi for Phase III trial of dengue therapyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-shijiazhuang-yiling-pharmaceutical-co-ltd-class-a-s-6c8686997a6409c5Pharma Surgeen2026-07-09T13:55:52.000ZPrice to earnings forward of Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A – SZSE:002603https://www.pharmaradar360.com/article/biotech-executive-keating-named-to-board-of-berkeley-heights-biopharma-kalaris-3f9a7b620670ea7bPharma Surgeen2026-07-09T13:43:29.000ZBiotech executive Keating named to board of Berkeley Heights biopharma Kalarishttps://www.pharmaradar360.com/article/astrazeneca-ionis-shares-slide-after-wainua-misses-target-in-heart-disease-trial-8916c763d718a7faPharma Surgeen2026-07-09T13:41:00.000ZAstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trialhttps://www.pharmaradar360.com/article/should-value-investors-buy-collegium-pharmaceutical-coll-stock-f7e57ce301393c87Pharma Surgeen2026-07-09T13:40:04.000ZShould Value Investors Buy Collegium Pharmaceutical (COLL) Stock?https://www.pharmaradar360.com/article/access-new-active-substance-and-biosimilar-work-sharing-initiatives-4389fa8c328281b5Pharma Surgeen2026-07-09T13:33:57.000ZAccess, new active substance and biosimilar work sharing initiativeshttps://www.pharmaradar360.com/article/why-biotech-revenue-projections-won-t-look-as-sunny-once-trump-tax-bill-hits-med-d3e9354ebdb0f2f0Pharma Surgeen2026-07-09T13:28:38.000ZWhy biotech revenue projections ‘won’t look as sunny’ once Trump tax bill hits Medicaid enrollmenthttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-370-23-im-8914a8d9390a32d2Pharma Surgeen2026-07-09T13:20:15.000ZWest Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $370.23, Implies 5% Upsidehttps://www.pharmaradar360.com/article/health-research-authority-annual-report-and-accounts-2025-to-2026-b267f58dcd06ad06Pharma Surgeen2026-07-09T13:12:10.000ZHealth Research Authority annual report and accounts 2025 to 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-07-09T13:00:03.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-09T13:00:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-09T13:00:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-09T13:00:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-09T13:00:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-09T13:00:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-09T13:00:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/it-s-time-to-build-a-more-scalable-connected-cro-6ee6a0c53fad1759Pharma Surgeen2026-07-09T12:56:53.000ZIt’s Time to Build a More Scalable, Connected CROhttps://www.pharmaradar360.com/article/wst-completes-smartdose-sale-to-abbvie-to-focus-on-core-growth-57c59d7fcaa24c27Pharma Surgeen2026-07-09T12:56:00.000ZWST Completes SmartDose Sale to AbbVie to Focus on Core Growthhttps://www.pharmaradar360.com/article/astrazeneca-licenses-sino-biopharma-respiratory-drug-in-200-million-upfront-deal-5e59d611cccc6e4aPharma Surgeen2026-07-09T12:49:45.000ZAstraZeneca licenses Sino Biopharma respiratory drug in $200 million upfront dealhttps://www.pharmaradar360.com/article/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-01af34cc5d056313Pharma Surgeen2026-07-09T12:45:15.000ZFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidatehttps://www.pharmaradar360.com/article/opus-genetics-expects-september-data-from-gene-therapy-trial-by-investing-com-5765fbf7922f8b30Pharma Surgeen2026-07-09T12:44:07.000ZOpus Genetics expects September data from gene therapy trial By Investing.comhttps://www.pharmaradar360.com/article/vanguard-health-care-vs-vaneck-pharmaceutical-how-do-these-etfs-stack-up-f56d45051d37992aPharma Surgeen2026-07-09T12:35:04.000ZVanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/fda-clears-fate-therapeutics-ft839-for-autoimmune-trial-push-7817185ed8a91721Pharma Surgeen2026-07-09T12:30:00.000ZFDA clears Fate Therapeutics' FT839 for autoimmune trial pushhttps://www.pharmaradar360.com/article/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-diff-42744a8c3ba092ffPharma Surgeen2026-07-09T12:16:20.000ZAnnual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2026 to 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-820ecbff0a7a966cPharma Surgeen2026-07-09T12:11:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-335870a76488db42Pharma Surgeen2026-07-09T12:10:59.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2027https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-ae1ac0815b2896b3Pharma Surgeen2026-07-09T12:10:29.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to October to December 2026https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-bfc75e0710215140Pharma Surgeen2026-07-09T12:09:49.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to July to September 2026https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267deccPharma Surgeen2026-07-09T12:09:22.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2026https://www.pharmaradar360.com/article/ca-auxilium-biotech-4dfdc6fde43e0d4ePharma Surgeen2026-07-09T12:03:21.000ZCA-AUXILIUM-BIOTECHhttps://www.pharmaradar360.com/article/zerostack-corp-secures-purchase-orders-for-up-to-us-14-7-million-of-inventory-fr-725b7f6698bda3e4Pharma Surgeen2026-07-09T12:01:00.000ZZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companieshttps://www.pharmaradar360.com/article/3-high-growth-glp-1-biotech-winners-to-buy-in-july-bff96628a3394d4aPharma Surgeen2026-07-09T12:00:59.000Z3 High Growth GLP-1 Biotech Winners to Buy in Julyhttps://www.pharmaradar360.com/article/phantom-hindfoot-ttc-tc-ball-tipped-guide-rod-50350c992cf9e824Pharma Surgeen2026-07-09T12:00:00.000ZPhantom® Hindfoot TTC/TC Ball Tipped Guide Rodhttps://www.pharmaradar360.com/article/om-warmer-d2e822d1212b5d63Pharma Surgeen2026-07-09T12:00:00.000ZºM Warmerhttps://www.pharmaradar360.com/article/astral-150tm-6eae77da267f4c7bPharma Surgeen2026-07-09T12:00:00.000ZAstral 150™https://www.pharmaradar360.com/article/research-use-of-uk-plasma-for-the-manufacture-of-five-further-plasma-derived-med-16a48978081dad48Pharma Surgeen2026-07-09T11:55:12.000ZResearch: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD riskhttps://www.pharmaradar360.com/article/pharmaceutical-technology-fe6a0a6f5e104550Pharma Surgeen2026-07-09T11:55:10.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/carbapenemase-producing-gram-negative-organisms-laboratory-surveillance-2476b0d93f0c3ea1Pharma Surgeen2026-07-09T11:52:29.000ZCarbapenemase-producing Gram-negative organisms: laboratory surveillancehttps://www.pharmaradar360.com/article/vertex-acquires-crinetics-in-10bn-endocrinology-deal-955b8f9fcbe04ad8Pharma Surgeen2026-07-09T11:36:29.000ZVertex acquires Crinetics in $10bn endocrinology dealhttps://www.pharmaradar360.com/article/the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-5105a372fc283456Pharma Surgeen2026-07-09T11:35:51.000ZThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rushhttps://www.pharmaradar360.com/article/gsk-cuts-losses-on-700m-upfront-alzheimer-s-collab-with-alector-following-2-clin-873f91b19acd8a25Pharma Surgeen2026-07-09T11:30:52.000ZGSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failureshttps://www.pharmaradar360.com/article/isaaa-launches-brief-57-in-manila-marking-two-decades-of-biotech-success-in-the-7b80dc8fda17251ePharma Surgeen2026-07-09T11:29:24.000ZISAAA Launches Brief 57 in Manila, Marking Two Decades of Biotech Success in the Philippineshttps://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49bPharma Surgeen2026-07-09T11:26:53.000ZHealth protection in children and young people's settings, including educationhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-09T11:22:09.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/3-reasons-to-buy-novo-nordisk-stock-6a25836f53ed473fPharma Surgeen2026-07-09T11:16:50.000Z3 Reasons to Buy Novo Nordisk Stockhttps://www.pharmaradar360.com/article/illicit-gain-combating-commission-widens-scope-placing-private-pharmaceutical-an-75eb0ecd2b029c16Pharma Surgeen2026-07-09T11:09:18.000ZIllicit Gain Combating Commission widens scope, placing private pharmaceutical and higher education institutions under direct controlhttps://www.pharmaradar360.com/article/science-in-motion-the-technologies-shaping-tomorrow-s-pharmaceutical-industry-e8c79cff4cdac921Pharma Surgeen2026-07-09T10:42:45.000ZScience in Motion: The Technologies Shaping Tomorrow's Pharmaceutical Industryhttps://www.pharmaradar360.com/article/30-2026-0da497c6889855bfPharma Surgeen2026-07-09T10:39:18.000ZΑΝΑΡΤΗΣΗ ΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΙΟΥΝΙΟΥ 2026https://www.pharmaradar360.com/article/teva-teva-advances-tev-408-into-phase-2b-for-vitiligo-after-early-progress-a0cc222fb5e8994ePharma Surgeen2026-07-09T10:37:40.000ZTeva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progresshttps://www.pharmaradar360.com/article/teva-teva-advances-tev-408-into-phase-2b-for-vitiligo-after-early-progress-544b715b3694bf23Pharma Surgeen2026-07-09T10:37:39.000ZTeva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progresshttps://www.pharmaradar360.com/article/is-viking-therapeutics-stock-going-to-100-a586155229d5e8b1Pharma Surgeen2026-07-09T10:37:09.000ZIs Viking Therapeutics Stock Going to $100?https://www.pharmaradar360.com/article/931-days-the-drug-approval-scandal-hiding-in-plain-sight-d7cbcfd237196033Pharma Surgeen2026-07-09T10:31:53.000Z931 days. The drug approval scandal hiding in plain sighthttps://www.pharmaradar360.com/article/biotech-s-digital-twin-dilemma-33b1623e57b488fdPharma Surgeen2026-07-09T10:30:28.000ZBiotech’s digital twin dilemmahttps://www.pharmaradar360.com/article/greenwood-capital-associates-llc-sells-142-082-shares-of-teva-pharmaceutical-ind-a2069f81be85211aPharma Surgeen2026-07-09T10:27:15.000ZGreenwood Capital Associates LLC Sells 142,082 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-summit-2026-3d9f9694a6622fe3Pharma Surgeen2026-07-09T10:25:31.000ZPharmaceutical Packaging Summit 2026https://www.pharmaradar360.com/article/evonik-invests-100-million-in-u-s-api-production-42c347c9fe6c8692Pharma Surgeen2026-07-09T10:13:39.000ZEvonik Invests $100 Million in U.S. API Productionhttps://www.pharmaradar360.com/article/does-america-s-new-favorite-anxiety-drug-have-a-dark-side-164fe18070cccd82Pharma Surgeen2026-07-09T10:07:49.000ZDoes America's New Favorite Anxiety Drug Have a Dark Side?https://www.pharmaradar360.com/article/class-2-medicines-recall-bristol-laboratories-limited-phenoxymethylpenicillin-25-01eaedddca8554b6Pharma Surgeen2026-07-09T10:07:16.000ZClass 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33https://www.pharmaradar360.com/article/roy-jakobs-to-join-gsk-board-as-non-executive-director-cb0d5a54ca69147cPharma Surgeen2026-07-09T10:00:00.000ZRoy Jakobs to join GSK Board as Non-Executive Directorhttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-09T09:52:04.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-a-disease-modeling-research-grant-and-an-accelerator-progr-136f87ff3f13b024Pharma Surgeen2026-07-09T09:49:12.000ZThe biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-upshttps://www.pharmaradar360.com/article/3bf4b717e6b46efbPharma Surgeen2026-07-09T09:47:56.000ZΕπαναδιατύπωση και Ανάρτηση Πρόσκλησης Εκδήλωσης Ενδιαφέροντος για Συνεργασία με Καθεστώς Α.Π.Υ. (Ορθή Επανάληψη)https://www.pharmaradar360.com/article/china-s-ascent-in-biotech-rousts-u-s-venture-capitalists-to-adapt-1a5c293d73b4074bPharma Surgeen2026-07-09T09:30:00.000ZChina’s Ascent in Biotech Rousts U.S. Venture Capitalists to Adapthttps://www.pharmaradar360.com/article/live-rats-houseflies-fda-suspends-license-of-mumbai-s-iconic-rustom-ice-cream-pa-3c2e88247ecf16c7Pharma Surgeen2026-07-09T09:30:00.000ZLive rats, houseflies: FDA suspends license of Mumbai's iconic 'Rustom' ice cream parlour over food safety violationshttps://www.pharmaradar360.com/article/pharmaceutical-industry-adopts-disease-classification-for-obesity-to-align-with-375b1a876faf7cc0Pharma Surgeen2026-07-09T09:19:17.000ZPharmaceutical Industry Adopts Disease Classification for Obesity to Align with GLP-1 Medication Markethttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-09T08:58:43.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-march-2026-4ecb811897116b1ePharma Surgeen2026-07-09T08:58:12.000ZDHSC: spending over £25,000, March 2026https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-april-2026-7a14df1ff5986eabPharma Surgeen2026-07-09T08:58:07.000ZDHSC: spending over £25,000, April 2026https://www.pharmaradar360.com/article/global-biotech-leaders-converge-at-uab-s-bac-2026-e11c4238554def98Pharma Surgeen2026-07-09T08:58:00.000ZGlobal Biotech Leaders Converge at UAB's BAC 2026https://www.pharmaradar360.com/article/does-tango-therapeutics-tngx-russell-growth-shift-reveal-its-true-biotech-identi-ddcebee6d0f6e18fPharma Surgeen2026-07-09T08:46:34.000ZDoes Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-tibet-rhodiola-pharmaceutical-holding-co-c-61effe861e03dfebPharma Surgeen2026-07-09T08:42:49.000ZEnterprise value to EBITDA forward of Tibet Rhodiola Pharmaceutical Holding Co. Class A – SSE:600211https://www.pharmaradar360.com/article/biotech-rally-rests-on-fundamentals-m-a-appetite-says-roty-s-faison-xlv-nysearca-4617a6dfa8480c43Pharma Surgeen2026-07-09T08:33:52.000ZBiotech rally rests on fundamentals, M&A appetite, says ROTY's Faison (XLV:NYSEARCA)https://www.pharmaradar360.com/article/the-quest-to-save-grace-and-clear-the-way-for-rare-disease-patients-everywhere-5c8d5ca3d7dce25fPharma Surgeen2026-07-09T08:31:50.000ZThe quest to save Grace — and clear the way for rare disease patients everywherehttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-09T08:30:15.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-09T08:30:15.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-07-09T08:30:14.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884Pharma Surgeen2026-07-09T08:30:13.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-09T08:30:12.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/life-sciences-jobs-plan-7418017e22c905c6Pharma Surgeen2026-07-09T08:30:12.000ZLife Sciences Jobs Planhttps://www.pharmaradar360.com/article/virus-reference-department-vrd-user-manual-bad0eec46821b469Pharma Surgeen2026-07-09T08:30:11.000ZVirus Reference Department (VRD): user manualhttps://www.pharmaradar360.com/article/measles-historic-confirmed-cases-notifications-and-deaths-55822ba8c9246f07Pharma Surgeen2026-07-09T08:30:09.000ZMeasles: Historic confirmed cases, notifications and deathshttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report-2955927e098c6836Pharma Surgeen2026-07-09T08:30:05.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: quarterly reporthttps://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78Pharma Surgeen2026-07-09T08:30:05.000ZUKHSA evidence reviewshttps://www.pharmaradar360.com/article/hand-hygiene-alternatives-to-soap-and-water-for-reducing-c-difficile-c51d2f2eaee482cdPharma Surgeen2026-07-09T08:30:03.000ZHand hygiene alternatives to soap and water for reducing C. difficilehttps://www.pharmaradar360.com/article/fda-plan-could-put-pharma-ads-out-of-reach-for-broadcasters-f66838d8b17a7d21Pharma Surgeen2026-07-09T08:30:00.000ZFDA Plan Could Put Pharma Ads Out Of Reach For Broadcasters.https://www.pharmaradar360.com/article/medipost-enrolls-and-treats-first-patient-in-u-s-phase-3-trial-of-cartistem-adva-cff97f3699db3787Pharma Surgeen2026-07-09T08:14:40.000ZMEDIPOST enrolls and treats first patient in U.S. Phase 3 trial of CARTISTEM, advancing U.S. commercializationhttps://www.pharmaradar360.com/article/astrazeneca-stock-drops-9-after-heart-drug-trial-miss-deals-rare-blow-to-pharma-9af4350aaad58778Pharma Surgeen2026-07-09T07:34:08.000ZAstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhousehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-moleculin-biotech-inc-nasdaq-mbrx-47e569ad7fa0c6c9Pharma Surgeen2026-07-09T07:12:52.000ZEnterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRXhttps://www.pharmaradar360.com/article/pharmaceutical-machine-learning-market-growth-to-accelerate-by-2035-amid-ai-driv-85facc4026702819Pharma Surgeen2026-07-09T07:06:10.000ZPharmaceutical Machine Learning Market Growth to Accelerate by 2035 Amid AI-Driven Bioprocessing Advances - News and Statisticshttps://www.pharmaradar360.com/article/setmelanotide-phase-3-trial-for-hypothalamic-obesity-published-in-nejm-50b9d1d1e1f5dfd1Pharma Surgeen2026-07-09T06:53:13.000ZSetmelanotide Phase 3 Trial for Hypothalamic Obesity Published in NEJMhttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-beauty-creams-after-tests-detect-excessive-m-3eb658af4516b369Pharma Surgeen2026-07-09T06:48:58.000ZMaharashtra FDA Warns Against Three Beauty Creams after Tests Detect Excessive Mercury, Lead Levelshttps://www.pharmaradar360.com/article/sunscreen-monograph-fda-adds-bemotrizinol-in-latest-update-4f568e05c16a4d70Pharma Surgeen2026-07-09T06:37:20.000ZSunscreen Monograph: FDA Adds Bemotrizinol in Latest Updatehttps://www.pharmaradar360.com/article/ionis-heart-drug-misses-key-goal-but-monotherapy-subgroup-hit-0cee8281df71d1dcPharma Surgeen2026-07-09T06:30:27.000ZIonis heart drug misses key goal, but monotherapy subgroup hithttps://www.pharmaradar360.com/article/novo-nordisk-launches-weekly-insulin-shot-awiqli-in-india-8e6e52751e41790ePharma Surgeen2026-07-09T06:23:00.000ZNovo Nordisk launches weekly insulin shot Awiqli in Indiahttps://www.pharmaradar360.com/article/accelerated-amortized-payment-of-convertible-bond-installment-c6b37637350b9310Pharma Surgeen2026-07-09T06:16:32.000ZAccelerated Amortized Payment of Convertible Bond Installmenthttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jointown-pharmaceutical-group-co-ltd-class-7fd9ca5c8f554de8Pharma Surgeen2026-07-09T06:10:53.000ZEnterprise value to EBITDA forward of Jointown Pharmaceutical Group Co., Ltd. Class A – SSE:600998https://www.pharmaradar360.com/article/price-to-sales-forward-of-ningbo-menovo-pharmaceutical-co-ltd-class-a-sse-603538-2096f17cc25616f7Pharma Surgeen2026-07-09T06:05:03.000ZPrice to sales forward of Ningbo Menovo Pharmaceutical Co., Ltd. Class A – SSE:603538https://www.pharmaradar360.com/article/raman-spectroscopic-systems-market-growth-outlook-to-2035-pharmaceutical-and-sem-d90d1ee212bedba8Pharma Surgeen2026-07-09T05:51:10.000ZRaman Spectroscopic Systems Market Growth Outlook to 2035: Pharmaceutical and Semiconductor Verticals Lead Demand - News and Statisticshttps://www.pharmaradar360.com/article/roche-receives-ce-mark-for-blood-test-to-identify-tuberculosis-infection-8152791d9f530be5Pharma Surgeen2026-07-09T05:00:00.000ZRoche receives CE Mark for blood test to identify tuberculosis infectionhttps://www.pharmaradar360.com/article/mumbai-s-k-rustom-ice-cream-parlour-fda-suspends-licence-after-live-rats-and-hou-5afb08cabccd027ePharma Surgeen2026-07-09T04:21:09.000ZMumbai’s K Rustom Ice Cream Parlour: FDA Suspends Licence After Live Rats and Houseflies Foundhttps://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-or-first-trust-biotech-fund-which-drug-maker-focused-ba8a96ae30031bedPharma Surgeen2026-07-09T04:10:40.000ZInvesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?https://www.pharmaradar360.com/article/fda-names-produce-safety-director-b900f12e916fa811Pharma Surgeen2026-07-09T04:08:41.000ZFDA names produce safety directorhttps://www.pharmaradar360.com/article/yomiuri-towa-pharmaceutical-aims-to-boost-production-capacity-with-planned-acqui-d4a68b9133ca3f33Pharma Surgeen2026-07-09T04:02:00.000ZYomiuri: Towa Pharmaceutical Aims to Boost Production Capacity with Planned Acquisition of Tanabe Pharma Subsidiaryhttps://www.pharmaradar360.com/article/glp-1-receptor-agonist-exposures-reported-to-poison-center-up-after-fda-approval-9b8563395cd3ad0dPharma Surgeen2026-07-09T04:00:00.000ZGLP-1 Receptor Agonist Exposures Reported to Poison Center Up After FDA Approval for Weight Losshttps://www.pharmaradar360.com/article/early-alert-convenience-kit-issue-from-medical-action-industries-88e120050a8ae2d2Pharma Surgeen2026-07-09T04:00:00.000ZEarly Alert: Convenience Kit Issue from Medical Action Industrieshttps://www.pharmaradar360.com/article/live-rats-houseflies-fda-suspends-license-of-mumbai-s-iconic-rustom-ice-cream-pa-393e4f488a7e119fPharma Surgeen2026-07-09T03:35:00.000ZLive rats, houseflies: FDA suspends license of Mumbai's iconic 'Rustom' ice cream parlour over food safety violationshttps://www.pharmaradar360.com/article/dea-s-own-pharmacologist-undercuts-marijuana-rescheduling-order-fde6c33089c4a055Pharma Surgeen2026-07-09T03:15:00.000ZDEA's Own Pharmacologist Undercuts Marijuana Rescheduling Orderhttps://www.pharmaradar360.com/article/sugar-land-supports-deliverit-group-s-new-pharmaceutical-facility-75da8bf9bd646dc6Pharma Surgeen2026-07-09T02:34:00.000ZSugar Land supports DeliverIt Group's new pharmaceutical facilityhttps://www.pharmaradar360.com/article/why-cmc-is-becoming-the-competitive-advantage-in-biotech-1b640514bae00d7aPharma Surgeen2026-07-09T02:01:09.000ZWhy CMC is Becoming the Competitive Advantage in Biotechhttps://www.pharmaradar360.com/article/biotech-m-a-surge-seen-as-going-beyond-blockbuster-deals-0b9f4765317dc0f8Pharma Surgeen2026-07-09T01:52:00.000ZBiotech M&A Surge Seen as Going Beyond Blockbuster Dealshttps://www.pharmaradar360.com/article/rhythm-pharmaceuticals-inc-announced-that-the-results-of-its-phase-3-transcend-c-cb8cdee824e66b7dPharma Surgeen2026-07-09T01:48:32.000ZRhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.https://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-00a2f17e5257582dPharma Surgeen2026-07-09T01:05:00.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-f8a6583bd54ddb5cPharma Surgeen2026-07-09T00:25:00.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-09T00:20:43.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/kalohexis-confidentially-files-ipo-to-back-obesity-and-cachexia-portfolio-939d3455269f177bPharma Surgeen2026-07-09T00:01:24.000ZKalohexis confidentially files IPO to back obesity and cachexia portfoliohttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-4a54cabad5933109Pharma Surgeen2026-07-09T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-990b788d53f42815Pharma Surgeen2026-07-09T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-09T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-8e3dc87507ebe370Pharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-5bf3abcc8552584dPharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-877f45a04e48322cPharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-af172079acca6dfaPharma Surgeen2026-07-09T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-467442fbd5737775Pharma Surgeen2026-07-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-d6ed57aed4cd7837Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-6e5706adc7c20334Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-7f18734f94e1cfa8Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-88ebaf9542169375Pharma Surgeen2026-07-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-340b298d91bb063ePharma Surgeen2026-07-09T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-614cc78d0939d709Pharma Surgeen2026-07-09T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-e47b4e03b0e64cffPharma Surgeen2026-07-09T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-51be4aa57449444aPharma Surgeen2026-07-09T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-bbe86a0bc0d4af84Pharma Surgeen2026-07-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/secretarial-comments-on-the-consensus-based-entity-s-cbe-battelle-memorial-insti-47ce5fabe71a06d5Pharma Surgeen2026-07-09T00:00:00.000ZSecretarial Comments on the Consensus-Based Entity's (CBE) (Battelle Memorial Institute) 2025 Activities: Report to Congress and the Secretary of the Department of Health and Human Serviceshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-d03cb9af82903cc0Pharma Surgeen2026-07-09T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/designation-of-phenethyl-halides-as-list-i-chemicals-87e71e02f52c9ce2Pharma Surgeen2026-07-09T00:00:00.000ZDesignation of Phenethyl Halides as List I Chemicalshttps://www.pharmaradar360.com/article/determination-that-tovalt-odt-zolpidem-tartrate-orally-disintegrating-tablets-5-b2fc1c38182caf6cPharma Surgeen2026-07-09T00:00:00.000ZDetermination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/more-than-500-children-ride-through-the-zoo-in-support-of-pediatric-cancer-resea-a35e5b310bd81571Pharma Surgeen2026-07-09T00:00:00.000ZMore Than 500 Children Ride Through the Zoo in Support of Pediatric Cancer Research at Cleveland Clinic Children’shttps://www.pharmaradar360.com/article/preliminary-application-of-antihypertensive-gene-detection-in-the-treatment-of-h-3acd1557d0c02aabPharma Surgeen2026-07-09T00:00:00.000ZPreliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension.https://www.pharmaradar360.com/article/artificial-intelligence-in-febrile-neutropenia-from-risk-scores-to-real-time-cli-2737a2fb0cc13d8bPharma Surgeen2026-07-09T00:00:00.000ZArtificial Intelligence in Febrile Neutropenia: From Risk Scores to Real-Time Clinical Decision Supporthttps://www.pharmaradar360.com/article/prospective-pan-cancer-phosphoproteomics-at-clinical-scale-extends-therapeutic-o-e15b508c0d2a060dPharma Surgeen2026-07-09T00:00:00.000ZProspective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncologyhttps://www.pharmaradar360.com/article/nonalcoholic-fatty-liver-disease-in-the-era-of-mafld-emerging-insights-into-mech-a4c595927eda82a5Pharma Surgeen2026-07-09T00:00:00.000ZNonalcoholic Fatty Liver Disease in the Era of MAFLD: Emerging Insights into Mechanisms, Diagnosis, and Personalized Management Global Burden and Economic Impacthttps://www.pharmaradar360.com/article/gene-therapy-in-glioblastoma-from-vector-engineering-to-immune-microenvironment-38b378a318f58adfPharma Surgeen2026-07-09T00:00:00.000ZGene Therapy in Glioblastoma: From Vector Engineering to Immune Microenvironment Reprogramminghttps://www.pharmaradar360.com/article/six-decades-of-kidney-transplantation-in-brazil-state-of-the-art-and-public-heal-435d88d46454e431Pharma Surgeen2026-07-09T00:00:00.000ZSix decades of kidney transplantation in Brazil: state of the art and public health implicationshttps://www.pharmaradar360.com/article/downregulation-of-il16-expression-induces-chemotherapeutic-drug-sensitivity-via-6cd7e3793206d162Pharma Surgeen2026-07-09T00:00:00.000ZDownregulation of IL16 Expression Induces Chemotherapeutic Drug Sensitivity via Increased Degradation of Mutant TP53 in Acute Myeloid Leukemia Cellshttps://www.pharmaradar360.com/article/figure-5-from-olamat-a-abu-owida-h-arabiat-a-ozel-p-2026-data-driven-prediction-e3030e2cb2974c1aPharma Surgeen2026-07-09T00:00:00.000ZFigure 5 from: Olamat A, Abu Owida H, Arabiat A, Ozel P (2026) Data-driven prediction of polydispersity in microfluidic liposome production for pharmaceutical formulation optimization. Pharmacia 73: e200497. https://doi.org/10.3897/pharmacia.73.e200497https://www.pharmaradar360.com/article/data-driven-stroke-prediction-leveraging-knn-for-early-detection-in-clinical-dat-1bd7030ab6713c9ePharma Surgeen2026-07-09T00:00:00.000ZData-Driven Stroke Prediction: Leveraging KNN for Early Detection in Clinical Datasetshttps://www.pharmaradar360.com/article/molecular-profiling-in-colon-cancer-integrating-research-with-clinical-practice-f017bdc6720cd8e3Pharma Surgeen2026-07-09T00:00:00.000ZMolecular Profiling in Colon Cancer: Integrating Research with Clinical Practicehttps://www.pharmaradar360.com/article/effect-of-an-ulva-lactuca-extract-on-systemic-antioxidant-and-inflammatory-bioma-7307401c073fdaccPharma Surgeen2026-07-09T00:00:00.000ZEffect of an Ulva lactuca Extract on Systemic Antioxidant and Inflammatory Biomarkers in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/practical-nutritional-strategies-to-attenuate-physiological-stress-in-adolescent-5c82c4cc4b4fbde4Pharma Surgeen2026-07-09T00:00:00.000ZPractical Nutritional Strategies to Attenuate Physiological Stress in Adolescent Soccer Players: A Comparative Trial of CoQ10 and Taurinehttps://www.pharmaradar360.com/article/implants-in-adolescents-clinical-outcomes-after-growth-pattern-adapted-implant-p-f89f01759a978c95Pharma Surgeen2026-07-09T00:00:00.000ZImplants in Adolescents: Clinical Outcomes After Growth-Pattern-Adapted Implant Placementhttps://www.pharmaradar360.com/article/dementia-and-the-impact-of-acetylcholinesterase-inhibitors-on-falls-fractures-an-d00830d7f09a79e1Pharma Surgeen2026-07-09T00:00:00.000ZDementia and the Impact of Acetylcholinesterase Inhibitors on Falls, Fractures and Mortality in a Geriatric Cohort: A 4-Year Follow-Up Studyhttps://www.pharmaradar360.com/article/development-and-external-validation-of-an-explainable-machine-learning-model-for-3b643ad91196d5afPharma Surgeen2026-07-09T00:00:00.000ZDevelopment and External Validation of an Explainable Machine-Learning Model for Predicting Postoperative Pulmonary Complications in Older Adults Undergoing Degenerative Spine Surgeryhttps://www.pharmaradar360.com/article/clinical-utility-of-repeat-sacroiliac-joint-mri-in-patients-evaluated-for-axial-12c34f3b71fe5263Pharma Surgeen2026-07-09T00:00:00.000ZClinical Utility of Repeat Sacroiliac Joint MRI in Patients Evaluated for Axial Spondyloarthritis: A Real-World Cohort Studyhttps://www.pharmaradar360.com/article/wear-smile-a-multidisciplinary-telemedicine-based-smoking-cessation-program-assi-194c4f222d19ef8cPharma Surgeen2026-07-09T00:00:00.000ZWear-Smile: A Multidisciplinary Telemedicine-Based Smoking Cessation Program Assisted by Wearable Monitoring Devices for Persons Who Smoke—Protocol for a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/tobacco-use-stigma-and-coping-in-lung-cancer-a-systematic-review-of-their-psycho-6a6c1e8d2bfd9c0bPharma Surgeen2026-07-09T00:00:00.000ZTobacco Use, Stigma, and Coping in Lung Cancer: A Systematic Review of Their Psychosocial Interactions and Clinical Implicationshttps://www.pharmaradar360.com/article/optimizing-systematic-endoscopic-lymph-node-staging-in-non-small-cell-lung-cance-406ffbf992bb65f2Pharma Surgeen2026-07-09T00:00:00.000ZOptimizing Systematic Endoscopic Lymph Node Staging in Non-Small Cell Lung Cancer: Proposals for Integrating the 9th Edition N-Staging Classification into Clinical Practicehttps://www.pharmaradar360.com/article/gonadotropin-therapy-in-idiopathic-hypogonadal-non-obstructive-azoospermia-aphro-23c4cc007f82d772Pharma Surgeen2026-07-09T00:00:00.000ZGonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3–4): a multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/pharmacology-education-embedded-within-longitudinal-community-patient-partnershi-502f0e326b37c966Pharma Surgeen2026-07-09T00:00:00.000ZPharmacology education embedded within longitudinal community patient partnerships: an interprofessional approach to medication safety and clinical applicationhttps://www.pharmaradar360.com/article/spontaneous-intracranial-hypotension-with-negative-brain-mri-findings-a-systemat-7d26a7908e95c60ePharma Surgeen2026-07-09T00:00:00.000ZSpontaneous intracranial hypotension with negative brain MRI findings: a systematic review of diagnostic strategies and clinical outcomeshttps://www.pharmaradar360.com/article/cell-and-extracellular-vesicle-therapies-for-aki-in-critical-care-clinical-trans-e3f589f0e315d3cePharma Surgeen2026-07-09T00:00:00.000ZCell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learnedhttps://www.pharmaradar360.com/article/a-genetic-and-clinical-risk-factor-algorithm-to-aid-in-identifying-new-cases-of-8f9546a2197bad2bPharma Surgeen2026-07-09T00:00:00.000ZA genetic and clinical risk factor algorithm to aid in identifying new cases of chronic kidney disease from the general populationhttps://www.pharmaradar360.com/article/clinical-evaluation-and-management-of-pediatric-enuresis-a-study-at-bmu-c59a87a768900974Pharma Surgeen2026-07-09T00:00:00.000ZClinical Evaluation and Management of Pediatric Enuresis: A Study at BMUhttps://www.pharmaradar360.com/article/evaluation-of-thyroid-disorders-in-children-with-emphasis-on-congenital-and-acqu-967d4f2cfd6a9eacPharma Surgeen2026-07-09T00:00:00.000ZEvaluation of Thyroid Disorders in Children with Emphasis on Congenital and Acquired Hypothyroidismhttps://www.pharmaradar360.com/article/evaluation-of-clinical-profiles-management-strategies-and-outcomes-of-patients-w-701d22eb67989088Pharma Surgeen2026-07-09T00:00:00.000ZEvaluation of Clinical Profiles, Management Strategies, and Outcomes of Patients with Acute Respiratory Distress in a Tertiary Emergency Departmenthttps://www.pharmaradar360.com/article/impact-of-sleep-loss-on-neurocognitive-function-and-reaction-speed-an-experiment-96d0c767a4107e99Pharma Surgeen2026-07-09T00:00:00.000ZImpact of Sleep Loss on Neurocognitive Function and Reaction Speed: An Experimental Analysishttps://www.pharmaradar360.com/article/comparative-evaluation-of-laparoscopic-versus-open-ventral-incisional-hernia-rep-58305ec751a71be1Pharma Surgeen2026-07-09T00:00:00.000ZComparative Evaluation of Laparoscopic versus Open Ventral Incisional Hernia Repairhttps://www.pharmaradar360.com/article/incidence-patterns-severity-and-outcomes-of-acute-poisoning-cases-presenting-to-d116f2e3d7a5586dPharma Surgeen2026-07-09T00:00:00.000ZIncidence Patterns, Severity, And Outcomes of Acute Poisoning Cases Presenting to a Tertiary Care Emergency Departmenthttps://www.pharmaradar360.com/article/evaluation-of-antidiabetic-drug-utilization-patterns-in-type-2-diabetes-mellitus-fcf81e6777504096Pharma Surgeen2026-07-09T00:00:00.000ZEvaluation of Antidiabetic Drug Utilization Patterns in Type 2 Diabetes Mellitus Patientshttps://www.pharmaradar360.com/article/evidence-grounded-ai-for-longitudinal-clinical-management-in-musculoskeletal-car-ce56338bf857f1a0Pharma Surgeen2026-07-09T00:00:00.000ZEvidence-grounded AI for longitudinal clinical management in musculoskeletal carehttps://www.pharmaradar360.com/article/fecal-microbiota-transplantation-improves-clinical-symptoms-and-promotes-intesti-6963c455715ed6cfPharma Surgeen2026-07-09T00:00:00.000ZFecal Microbiota Transplantation Improves Clinical Symptoms and Promotes Intestinal Microecological Remodeling in Patients with Constipation Complicated by Anxiety: A Multi-omics Studyhttps://www.pharmaradar360.com/article/clinical-prompt-enhanced-deep-learning-model-for-precise-preoperative-prediction-fad923777ba2bb76Pharma Surgeen2026-07-09T00:00:00.000ZClinical-Prompt-Enhanced Deep Learning Model for Precise Preoperative Prediction of Gallbladder Polypoid Lesion Subtypeshttps://www.pharmaradar360.com/article/clinical-study-evaluating-the-perioperative-combination-of-duloxetine-and-pregab-7ca0a473940b4171Pharma Surgeen2026-07-09T00:00:00.000ZClinical study evaluating the perioperative combination of duloxetine and pregabalin to improve postoperative pain after mega-liposuction surgery under general anesthesia: a double-blind randomized clinical trialhttps://www.pharmaradar360.com/article/non-invasive-brain-stimulation-for-parkinson-s-disease-therapeutic-applications-55032b1b1ca66c3bPharma Surgeen2026-07-09T00:00:00.000ZNon-invasive Brain Stimulation for Parkinson’s Disease: Therapeutic Applications and Clinical Perspectiveshttps://www.pharmaradar360.com/article/association-between-denosumab-therapy-and-hypocalcemia-influence-of-concomitant-c251c430bbcf462fPharma Surgeen2026-07-09T00:00:00.000ZAssociation between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parametershttps://www.pharmaradar360.com/article/optimizing-high-drug-loaded-spray-dried-antibody-fragment-formulations-for-susta-ea7b2e95eb06a2f5Pharma Surgeen2026-07-09T00:00:00.000ZOptimizing high-drug-loaded spray-dried antibody fragment formulations for sustained delivery: influence of excipient composition and humidity on long-term stabilityhttps://www.pharmaradar360.com/article/understanding-the-small-print-a-5-year-review-of-readability-in-phase-i-trial-in-960e2329720cf92bPharma Surgeen2026-07-09T00:00:00.000ZUnderstanding the small print: a 5-year review of readability in phase I trial information leafletshttps://www.pharmaradar360.com/article/sustained-clinical-benefit-of-idursulfase-beta-in-mucopolysaccharidosis-ii-two-y-fa3f249bed1a3559Pharma Surgeen2026-07-09T00:00:00.000ZSustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfasehttps://www.pharmaradar360.com/article/effects-of-28-day-astaxanthin-supplementation-on-psychological-fatigue-and-bioch-09cdb7af5709af3cPharma Surgeen2026-07-09T00:00:00.000ZEffects of 28-day astaxanthin supplementation on psychological fatigue and biochemical markers in taekwondo athletes: a randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-critically-ill-women-with-gynecologic-m-5335f3dd49a6e2a4Pharma Surgeen2026-07-09T00:00:00.000ZClinical characteristics and outcomes of critically ill women with gynecologic malignancies: a two-database retrospective study using MIMIC-IV v3.1 and eICU-CRD v2.0https://www.pharmaradar360.com/article/knowledge-improvement-on-premarital-hiv-counseling-with-pause-flipchart-versus-c-a5794c2bb94c3014Pharma Surgeen2026-07-09T00:00:00.000ZKnowledge improvement on premarital HIV counseling with PAUSE© flipchart versus conventional method: a cluster randomised controlled trialhttps://www.pharmaradar360.com/article/therapeutic-drug-monitoring-of-linezolid-in-real-world-clinical-practice-determi-aa76810a91214cadPharma Surgeen2026-07-09T00:00:00.000ZTherapeutic Drug Monitoring of Linezolid in Real-World Clinical Practice: Determinants of Exposure, Dose Optimization and Hematological Toxicityhttps://www.pharmaradar360.com/article/beyond-amplification-precision-approaches-to-targeting-her2-7c5d012331d4c8e0Pharma Surgeen2026-07-09T00:00:00.000ZBeyond amplification: precision approaches to targeting HER2https://www.pharmaradar360.com/article/valve-strands-in-patients-with-infective-endocarditis-8c3306d88094f123Pharma Surgeen2026-07-09T00:00:00.000ZValve Strands in Patients With Infective Endocarditishttps://www.pharmaradar360.com/article/cofactor-functions-of-magnesium-in-complement-activation-and-antimicrobial-respo-803c5a7c4b2b32edPharma Surgeen2026-07-09T00:00:00.000ZCofactor functions of magnesium in complement activation and antimicrobial responseshttps://www.pharmaradar360.com/article/neonatal-genetic-sequencing-as-a-first-tier-option-a-real-world-clinical-impleme-c2fc85228b246432Pharma Surgeen2026-07-09T00:00:00.000ZNeonatal genetic sequencing as a first-tier option: a real-world clinical implementation study in Northern Chinahttps://www.pharmaradar360.com/article/agentic-ai-driven-closed-loop-analytical-systems-for-autonomous-pharmaceutical-m-29a015a46260f4e1Pharma Surgeen2026-07-09T00:00:00.000ZAgentic AI-driven closed-loop analytical systems for autonomous pharmaceutical method development and regulatory-aware analysishttps://www.pharmaradar360.com/article/extracellular-synthesis-of-cenps-and-znnps-using-thermophilic-anoxybacillus-flav-bd256bdd9072a73ePharma Surgeen2026-07-09T00:00:00.000ZExtracellular synthesis of CeNPs and ZnNPs using thermophilic Anoxybacillus flavithermus and Geobacillus stearothermophilus bacteria, and their biological activitieshttps://www.pharmaradar360.com/article/breast-conserving-therapy-versus-mastectomy-outcomes-across-different-clinical-c-56e5dafdf9ede7e0Pharma Surgeen2026-07-09T00:00:00.000ZBreast Conserving Therapy Versus Mastectomy: Outcomes Across Different Clinical Characteristicshttps://www.pharmaradar360.com/article/active-recruitment-for-vaccination-of-patients-with-solid-organ-cancer-through-t-99f0097c95cd5500Pharma Surgeen2026-07-09T00:00:00.000ZActive recruitment for vaccination of patients with solid-organ cancer through the surgical pathwayhttps://www.pharmaradar360.com/article/deciphering-b-cell-maturation-dynamics-in-hyper-igm-syndromes-f1dbbde19de7559dPharma Surgeen2026-07-09T00:00:00.000ZDeciphering B cell Maturation Dynamics in Hyper-IgM Syndromeshttps://www.pharmaradar360.com/article/from-competence-to-entrustment-strengthening-clinical-autonomy-within-the-esicm-b691d4e2a8387fc4Pharma Surgeen2026-07-09T00:00:00.000ZFrom competence to entrustment: strengthening clinical autonomy within the ESICM educational frameworkhttps://www.pharmaradar360.com/article/domain-knowledge-guided-for-varicose-vein-classification-with-adaptive-clinical-3aebce2ccf15e826Pharma Surgeen2026-07-09T00:00:00.000ZDomain Knowledge Guided for Varicose Vein Classification with Adaptive Clinical Expertshttps://www.pharmaradar360.com/article/diagnostic-pitfalls-of-action-induced-tremor-a-case-report-of-benign-adult-famil-5ace3d739e6f8a3bPharma Surgeen2026-07-09T00:00:00.000ZDiagnostic Pitfalls of Action‐Induced Tremor: A Case Report of Benign Adult Familial Myoclonic Epilepsy Treated with Thalamic Lesioninghttps://www.pharmaradar360.com/article/mental-health-and-serious-drug-crime-a-case-control-study-bba53f44bf1e7a3bPharma Surgeen2026-07-09T00:00:00.000ZMental Health and Serious Drug Crime: A Case–Control Studyhttps://www.pharmaradar360.com/article/nct07694219-bowen-therapy-and-mcgill-stabilization-exercises-in-chronic-low-back-eb02e56314256441Pharma Surgeen2026-07-09T00:00:00.000ZNCT07694219: Bowen Therapy and McGill Stabilization Exercises in Chronic Low Back Painhttps://www.pharmaradar360.com/article/nct07692841-single-dose-vs-divided-dose-g-csf-for-stem-cell-mobilization-in-heal-ea150d25a6ceb2baPharma Surgeen2026-07-09T00:00:00.000ZNCT07692841: Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donorshttps://www.pharmaradar360.com/article/nct07692347-global-myofascial-treatment-with-focused-shockwave-for-non-specific-9ab3aed65c3585b3Pharma Surgeen2026-07-09T00:00:00.000ZNCT07692347: Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: a Randomized Control Trial.https://www.pharmaradar360.com/article/nct07692230-mri-driven-precision-typing-and-response-prediction-in-luminal-breas-32651d7a60eaddbcPharma Surgeen2026-07-09T00:00:00.000ZNCT07692230: MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancerhttps://www.pharmaradar360.com/article/nct07691801-study-on-the-application-of-liquid-chromatography-tandem-mass-spectr-5186da9590dc07c5Pharma Surgeen2026-07-09T00:00:00.000ZNCT07691801: Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Testhttps://www.pharmaradar360.com/article/nct07691515-a-phase-iii-trial-of-intraarterial-therapies-plus-tislelizumab-plus-445bcec385ae5ea6Pharma Surgeen2026-07-09T00:00:00.000ZNCT07691515: A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinomahttps://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00Pharma Surgeen2026-07-09T00:00:00.000ZNCT07686380: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapyhttps://www.pharmaradar360.com/article/nct07683104-natural-history-of-trisomy-8-associated-autoinflammatory-disease-tri-a10b26c09d1352edPharma Surgeen2026-07-09T00:00:00.000ZNCT07683104: Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disordershttps://www.pharmaradar360.com/article/nct07669363-hexaminolevulinate-photodynamic-therapy-hal-pdt-with-deferred-surger-a7910cbb378826b5Pharma Surgeen2026-07-09T00:00:00.000ZNCT07669363: Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)https://www.pharmaradar360.com/article/nct07640191-feasibility-study-of-the-iveacare-neuromodulation-system-for-the-tre-5513f58d514aacccPharma Surgeen2026-07-09T00:00:00.000ZNCT07640191: Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsyhttps://www.pharmaradar360.com/article/nct07629440-a-study-to-learn-about-how-a-new-pneumococcal-vaccine-works-in-infan-7854a35d3058f848Pharma Surgeen2026-07-09T00:00:00.000ZNCT07629440: A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.https://www.pharmaradar360.com/article/nct07619495-injectable-semaglutide-vs-dulaglutide-in-individuals-at-cardiovascul-63b6e60c1a110c1bPharma Surgeen2026-07-09T00:00:00.000ZNCT07619495: Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Riskhttps://www.pharmaradar360.com/article/nct07571109-amaze-4-a-research-study-investigating-how-well-the-medicine-nnc0487-66707094d9db7bcaPharma Surgeen2026-07-09T00:00:00.000ZNCT07571109: AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoeahttps://www.pharmaradar360.com/article/nct07567846-a-study-evaluating-the-safety-pharmacokinetics-and-preliminary-activ-c0640e7d3df3c055Pharma Surgeen2026-07-09T00:00:00.000ZNCT07567846: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancerhttps://www.pharmaradar360.com/article/nct07545317-real-world-study-of-il-23-inhibitors-in-active-crohn-s-disease-9b2b7a386017370ePharma Surgeen2026-07-09T00:00:00.000ZNCT07545317: Real-World Study of IL-23 Inhibitors in Active Crohn's Diseasehttps://www.pharmaradar360.com/article/nct07540988-fibroneer-act-a-study-to-test-whether-nerandomilast-helps-people-wit-cfc189fafaf99948Pharma Surgeen2026-07-09T00:00:00.000ZNCT07540988: FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progressionhttps://www.pharmaradar360.com/article/nct07525167-early-prediction-of-bronchopulmonary-dysplasia-in-preterm-infants-us-7209291ff6bdca5fPharma Surgeen2026-07-09T00:00:00.000ZNCT07525167: Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Datahttps://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762Pharma Surgeen2026-07-09T00:00:00.000ZNCT07524530: Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancershttps://www.pharmaradar360.com/article/nct07520734-clinical-outcomes-after-laser-hemorrhoidoplasty-e44b23a93c95b100Pharma Surgeen2026-07-09T00:00:00.000ZNCT07520734: Clinical Outcomes After Laser Hemorrhoidoplastyhttps://www.pharmaradar360.com/article/nct07421167-a-study-to-assess-the-tolerability-of-ianalumab-vay736-with-investig-25fd800221bd14b1Pharma Surgeen2026-07-09T00:00:00.000ZNCT07421167: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)https://www.pharmaradar360.com/article/nct07416188-novel-indenoisoquinolone-cmyc-topoisomerase-1-inhibitor-lmp744-in-re-dcf6d8e23b23af45Pharma Surgeen2026-07-09T00:00:00.000ZNCT07416188: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct07243925-effect-of-family-participation-based-intervention-before-coronary-ar-fa975e75a7669189Pharma Surgeen2026-07-09T00:00:00.000ZNCT07243925: Effect of Family Participation-Based Intervention Before Coronary Artery Bypass Grafting (CABG) on Patients' Anxiety, Independence, and Psychological Resilience: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07161414-a-study-to-investigate-the-pharmacokinetics-and-safety-of-subcutaneo-be8949531768a777Pharma Surgeen2026-07-09T00:00:00.000ZNCT07161414: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapyhttps://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4Pharma Surgeen2026-07-09T00:00:00.000ZNCT06948097: Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodieshttps://www.pharmaradar360.com/article/nct06917209-evaluation-of-the-efficacy-of-dissociation-focused-cognitive-behavio-cf98ad12e30c9d62Pharma Surgeen2026-07-09T00:00:00.000ZNCT06917209: Evaluation of the Efficacy of Dissociation-Focused Cognitive Behavior Therapyhttps://www.pharmaradar360.com/article/nct06808477-a-study-of-bbt001-in-healthy-volunteers-hvs-and-in-adult-patients-wi-500d0949dbf9c1fcPharma Surgeen2026-07-09T00:00:00.000ZNCT06808477: A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)https://www.pharmaradar360.com/article/nct06483139-novel-treatments-in-improving-renal-outcomes-in-light-chain-cast-nep-d7d62b05a5b82639Pharma Surgeen2026-07-09T00:00:00.000ZNCT06483139: Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathyhttps://www.pharmaradar360.com/article/nct06149481-phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-tri-adbb0db592ba30ecPharma Surgeen2026-07-09T00:00:00.000ZNCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)https://www.pharmaradar360.com/article/nct05564377-targeted-therapy-directed-by-genetic-testing-in-treating-patients-wi-2008e0086f4d7541Pharma Surgeen2026-07-09T00:00:00.000ZNCT05564377: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trialhttps://www.pharmaradar360.com/article/nct05412212-brief-educational-video-for-patients-prescribed-ltbi-treatment-936bb38c8aed148bPharma Surgeen2026-07-09T00:00:00.000ZNCT05412212: Brief Educational Video for Patients Prescribed LTBI Treatmenthttps://www.pharmaradar360.com/article/nct05335876-long-term-follow-up-of-patients-with-spinal-muscular-atrophy-treated-2a9dbae97e53e9e4Pharma Surgeen2026-07-09T00:00:00.000ZNCT05335876: Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trialshttps://www.pharmaradar360.com/article/nct05258071-a-clinical-study-evaluating-efficacy-of-pirepemat-on-falls-frequency-b2c5b01c6d12a7f0Pharma Surgeen2026-07-09T00:00:00.000ZNCT05258071: A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)https://www.pharmaradar360.com/article/nct05143957-a-study-to-evaluate-sapablursen-formerly-isis-702843-ionis-tmprss6-l-728cfeaa39f55fa6Pharma Surgeen2026-07-09T00:00:00.000ZNCT05143957: A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Verahttps://www.pharmaradar360.com/article/nct04439201-testing-palbociclib-pd-0332991-as-a-potential-targeted-treatment-in-ba5a073bb855bcf3Pharma Surgeen2026-07-09T00:00:00.000ZNCT04439201: Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)https://www.pharmaradar360.com/article/nct04181060-osimertinib-with-or-without-bevacizumab-as-initial-treatment-for-pat-1d873460026613bfPharma Surgeen2026-07-09T00:00:00.000ZNCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancerhttps://www.pharmaradar360.com/article/nct03834493-study-of-pembrolizumab-mk-3475-plus-enzalutamide-versus-placebo-plus-341a6401bae591f4Pharma Surgeen2026-07-09T00:00:00.000ZNCT03834493: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)https://www.pharmaradar360.com/article/nct03192267-early-rheumatoid-arthritis-lung-disease-study-ec4f7abe65c438baPharma Surgeen2026-07-09T00:00:00.000ZNCT03192267: Early Rheumatoid Arthritis Lung Disease Studyhttps://www.pharmaradar360.com/article/nct03000244-long-term-follow-up-of-patients-undergoing-hematopoietic-stem-cell-t-17c3ccd3bbfd7d88Pharma Surgeen2026-07-09T00:00:00.000ZNCT03000244: Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapyhttps://www.pharmaradar360.com/article/nct02977299-comparative-effectiveness-research-trial-for-antidepressant-incomple-0969ffa471f69e98Pharma Surgeen2026-07-09T00:00:00.000ZNCT02977299: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRDhttps://www.pharmaradar360.com/article/nct01883505-a-safety-tolerability-and-levodopa-pharmacokinetics-study-of-repeate-a8d4b238e5c7532bPharma Surgeen2026-07-09T00:00:00.000ZNCT01883505: A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patientshttps://www.pharmaradar360.com/article/fda-plans-rules-to-rein-in-drug-ads-enable-proactive-release-of-crls-and-more-d37baf91a70cad39Pharma Surgeen2026-07-08T23:20:00.000ZFDA plans rules to rein in drug ads, enable proactive release of CRLs, and morehttps://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-or-first-trust-biotech-fund-which-drug-maker-focused-2430afb86acbb3f8Pharma Surgeen2026-07-08T23:04:00.000ZInvesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?https://www.pharmaradar360.com/article/life-sciences-sector-plan-one-year-on-9b7efa9f764f7323Pharma Surgeen2026-07-08T23:01:03.000ZLife Sciences Sector Plan: One Year Onhttps://www.pharmaradar360.com/article/life-sciences-sector-plan-084e6253e9ed0a39Pharma Surgeen2026-07-08T23:01:03.000ZLife Sciences Sector Planhttps://www.pharmaradar360.com/article/uk-life-sciences-attracts-3bn-investment-creating-jobs-and-faster-patient-treatm-69c4239af0302634Pharma Surgeen2026-07-08T23:01:00.000ZUK life sciences attracts £3bn investment, creating jobs and faster patient treatmentshttps://www.pharmaradar360.com/article/organ-on-a-chip-organoids-but-drug-testing-on-whole-organs-this-startup-is-betti-1720d0355f4972a3Pharma Surgeen2026-07-08T22:25:50.000ZOrgan-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On Ithttps://www.pharmaradar360.com/article/local-biotech-companies-may-get-option-to-report-finances-twice-a-year-bac12ecdb36261f8Pharma Surgeen2026-07-08T21:22:00.000ZLocal biotech companies may get option to report finances twice a yearhttps://www.pharmaradar360.com/article/rhythm-pharmaceuticals-announces-nejm-publication-of-phase-3-transcend-trial-res-eca70af17bdc7025Pharma Surgeen2026-07-08T21:20:00.000ZRhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesityhttps://www.pharmaradar360.com/article/rhythm-s-obesity-drug-data-lands-in-nejm-after-52-week-phase-3-trial-9d00cd3cfdd53adbPharma Surgeen2026-07-08T21:07:00.000ZRhythm’s obesity drug data lands in NEJM after 52-week Phase 3 trialhttps://www.pharmaradar360.com/article/alpha-1-antitrypsin-deficiency-drug-enters-ph3-trial-d10b7516dbf00a3ePharma Surgeen2026-07-08T20:44:23.000ZAlpha-1 Antitrypsin Deficiency Drug Enters Ph3 Trialhttps://www.pharmaradar360.com/article/fda-unveils-3-year-blueprint-to-expand-drug-development-for-minor-uses-and-minor-b56a5314f51a8930Pharma Surgeen2026-07-08T20:36:05.000ZFDA unveils 3-year blueprint to expand drug development for minor uses and minor specieshttps://www.pharmaradar360.com/article/new-york-pushes-to-become-major-us-biotech-hub-cebd85d9e27f0eaePharma Surgeen2026-07-08T20:33:53.000ZNew York pushes to become major US biotech hubhttps://www.pharmaradar360.com/article/amneal-and-adalvo-announce-fda-acceptance-for-review-of-two-u-s-andas-for-generi-b04164da9303bf4cPharma Surgeen2026-07-08T20:30:00.000ZAmneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjectorhttps://www.pharmaradar360.com/article/180m-financing-supports-head-to-head-phase-3-ipf-drug-trial-64f16c77cbecb785Pharma Surgeen2026-07-08T20:20:45.000Z$180M financing supports head-to-head Phase 3 IPF drug trialhttps://www.pharmaradar360.com/article/alector-alec-sees-gsk-end-antibody-collaboration-while-repaying-10-4m-loan-48577b2f6951ed56Pharma Surgeen2026-07-08T20:06:23.000ZAlector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loanhttps://www.pharmaradar360.com/article/tarsus-pays-75m-for-eye-drug-candidate-with-phase-3-ahead-2912c59964222548Pharma Surgeen2026-07-08T20:05:00.000ZTarsus pays $75M for eye drug candidate with Phase 3 aheadhttps://www.pharmaradar360.com/article/ai-as-reinvention-pharmexec-f080108223da0a0cPharma Surgeen2026-07-08T19:45:44.000ZAI as Reinvention | PharmExechttps://www.pharmaradar360.com/article/rsv-antiviral-zelicapavir-enters-late-stage-clinical-trials-db65899d03b76d21Pharma Surgeen2026-07-08T19:44:22.000ZRSV Antiviral Zelicapavir Enters Late-stage Clinical Trialshttps://www.pharmaradar360.com/article/biotech-merger-tests-ai-patient-stratification-against-ra-s-70-treatment-gap-865093ff89937872Pharma Surgeen2026-07-08T19:41:34.000ZBiotech Merger Tests AI Patient Stratification Against RA’s 70% Treatment Gaphttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-consob-approved-the-offer-document-5adb109bdf0f1a80Pharma Surgeen2026-07-08T19:13:20.000ZOn behalf of Respighi BidCo S.p.A – CONSOB approved the Offer Documenthttps://www.pharmaradar360.com/article/major-biotech-company-laying-off-103-more-employees-in-fifth-round-of-cuts-since-5ec6e105d5055c29Pharma Surgeen2026-07-08T18:19:00.000ZMajor biotech company laying off 103 more employees in fifth round of cuts since mid-2025https://www.pharmaradar360.com/article/fda-collects-ghee-honey-samples-during-inspection-a4baddaefd6523d2Pharma Surgeen2026-07-08T18:03:15.000ZFDA collects ghee, honey samples during inspectionhttps://www.pharmaradar360.com/article/scoop-to-soup-fda-freezes-licence-of-mumbai-s-iconic-ice-cream-outlet-after-rats-996f28e08938c082Pharma Surgeen2026-07-08T17:53:00.000ZScoop to soup: FDA freezes licence of Mumbai's iconic ice cream outlet after rats found on premiseshttps://www.pharmaradar360.com/article/dea-proposes-schedule-i-ban-for-the-first-gas-station-drug-tianeptine-2ddd241517ee489aPharma Surgeen2026-07-08T17:34:45.000ZDEA Proposes Schedule I Ban for the First “Gas Station Drug," Tianeptinehttps://www.pharmaradar360.com/article/fda-halts-release-of-new-drug-rejection-letters-while-working-to-formalize-polic-338fd545bd0f3425Pharma Surgeen2026-07-08T17:33:27.000ZFDA halts release of new drug rejection letters while working to formalize policyhttps://www.pharmaradar360.com/article/errant-fda-policy-and-dramatic-rise-of-device-and-drug-recalls-news-article-ae29a2e4decd1f3dPharma Surgeen2026-07-08T17:12:56.000ZErrant FDA Policy and Dramatic Rise of Device and Drug Recalls : News Articlehttps://www.pharmaradar360.com/article/powering-scientific-discovery-byokg-and-graphrag-for-intelligent-pharmaceutical-155b1e0c49a833f7Pharma Surgeen2026-07-08T16:57:12.000ZPowering scientific discovery: BYOKG and GraphRAG for intelligent pharmaceutical researchhttps://www.pharmaradar360.com/article/amgen-ecovation-how-amgen-builds-sustainability-into-biotech-52bd0d751ed179dcPharma Surgeen2026-07-08T16:40:16.000ZAmgen Ecovation®: How Amgen Builds Sustainability Into Biotechhttps://www.pharmaradar360.com/article/pharmaceutical-company-to-build-rare-manufacturing-facility-in-sugar-land-02ca74d9c23c55ccPharma Surgeen2026-07-08T16:24:00.000ZPharmaceutical company to build rare manufacturing facility in Sugar Landhttps://www.pharmaradar360.com/article/campylobacter-infection-annual-data-02c1dd6f758d5376Pharma Surgeen2026-07-08T16:20:55.000ZCampylobacter infection: annual datahttps://www.pharmaradar360.com/article/why-the-government-must-urgently-raise-the-nice-cost-effectiveness-threshold-1b734b641caf26ebPharma Surgeen2026-07-08T16:16:12.000ZWhy the government must urgently raise the NICE cost-effectiveness thresholdhttps://www.pharmaradar360.com/article/understanding-nhs-medicines-spending-in-england-8db3f6e3ab405423Pharma Surgeen2026-07-08T16:12:08.000ZUnderstanding NHS medicines spending in Englandhttps://www.pharmaradar360.com/article/abpi-response-to-life-sciences-competitiveness-indicators-8b0806f016033b51Pharma Surgeen2026-07-08T16:10:13.000ZABPI response to Life Sciences Competitiveness Indicatorshttps://www.pharmaradar360.com/article/astrazeneca-gsk-intensify-china-ties-with-sino-biopharm-deals-d60ddd5088aff017Pharma Surgeen2026-07-08T16:05:55.000ZAstraZeneca, GSK intensify China ties with Sino Biopharm dealshttps://www.pharmaradar360.com/article/fda-suspends-licence-of-iconic-mumbai-ice-cream-outlet-k-rustom-over-food-safety-c7e9e6ac4edf5e59Pharma Surgeen2026-07-08T15:46:14.000ZFDA suspends licence of iconic Mumbai ice cream outlet K Rustom over food safety violations